Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Akari Therapeutics stock opened at $2.24 on Thursday. The company has a 50-day moving average price of $3.23 and […]
More Stories
The Color Revolution Comes Home: Ex-USAID Operatives, DSA Networks, and a Playbook Aimed at the American Republic
By Stephen Zogopoulos, USNN World News In the interview titled “DataRepublican: The Democrat Plan For A Color Revolution: Everything You...
Trump Admin Can Detain Illegal Immigrants Without Bond Hearings: Appeals Court
By Zachary Stieber President Donald Trump’s administration can hold illegal immigrants in detention without bond hearings, a full federal appeals...
Florida Mayor Arrested After Authorities Say She Paid Herself and Family State COVID Funds
By Jill McLaughlin State authorities arrested the mayor of the central Florida city of Kissimmee on Oct. 21, charging her...
American Express Laying Off 5 Percent of Workforce
By Andrew Moran American Express said it is laying off about 5 percent of its workforce. The global payment services...
Typhoon Champi Leaves 1 Dead, 350 Injured in Taiwan; Alters US-Japan Military Exercise
By Arthur Zhang Typhoon Champi left one person dead and 350 injured in Taiwan, disrupting air and rail travel and...
Russian Diesel Expected to Arrive on Nov. 7 After Trump-Putin Deal
By Tom Ozimek A tanker carrying 40,000 metric tons of Russian diesel is heading toward New York following a deal...